Zanidatamab, an anti-HER2 bispecific antibody, demonstrated anti-tumor activity in a phase I study of 20 patients with metastatic HER2-positive biliary tract cancer whose disease progressed on prior therapy, with an ORR of 40% [38]. This evidence concerns the gene ERBB2 and neoplasm.